(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
"Efficacy and Safety of Fidaxomicin vs. Vancomycin in Clostridium difficile Infection in 2 Randomized Controlled Trials with 1105 Patients" | |
Oral Presentation: Derrick Crook, M.D. | |
Saturday, October 23, 2010 3:30pm Pacific Time | |
Session: 146 Oral Abstract Session: Clostridium difficile | |
Presentation number: 1417 | |
"Categorization of Patients in a Large Multicenter Study of Clostridium difficile Infection Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence" | |
Oral Presentation: Mark A. Miller, M.D. | |
Saturday, October 23, 2010 2:00pm Pacific Time | |
Session: 146 Oral Abstract Session: Clostridium difficile | |
Presentation number: 1411 | |
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI) and we recently initiated a rolling submission of our NDA filing to the FDA, and have filed a MAA to the EMA (Europe). Pruvel is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea and we plan to have a NDA submitted to the FDA in the first quarter of 2011. Additional information can be found at http://www.optimerpharma.com.
Contacts | |
Optimer Pharmaceuticals, Inc. | |
Christina Donaghy, Corporate Communications Manager | |
John D. Prunty, Chief Financial Officer & VP Finance | |
858-909-0736 | |
Canale Communications, Inc. | |
Jason I. Spark, Senior Vice President | |
619-849-6005 | |
SOURCE Optimer Pharmaceuticals, Inc.
